NewsRoom Articles - Page 110 of 154 - PsychedelicNewsWire (PNW)

MondayJan 04, 2021 1:15 pm

VC Fund Committed to Psychedelic Medicine Development Launched in UK

In the past couple of years, biopharmaceutical firms focused on psychedelic medicines have increased in number. Two weeks ago, UK’s first psychedelic investment fund was launched. The fund is committed to psychedelic health care and hopes to invest in psychedelic medicines to treat conditions such as anxiety, addiction and depression. The fund was established by VC Neo Kuma Ventures, an organization based in London, which was formed by Nick David, Clara Burtenshaw and Sean McLintock in 2019. In the same year, the founders of Neo Kuma gave their support to ATAI Life Sciences AG, the co-owner of COMPASS Pathways (NASDAQ:…

ThursdayDec 31, 2020 12:25 pm

Shrooms Vs. LSD: Are They the Same?

During the general elections held in November 2020, Oregon voters made history by passing Measure 110 and Measure 109. The former decriminalizes the possession of small amounts of all illicit substances while the latter allows adult use of psilocybin mushrooms in a therapeutic setting. Psychedelics are made up of various substances including LSD, commonly known as acid, and “magic” mushrooms, or psilocybin mushrooms. While there are some similarities between both LSD and mushrooms, both may elicit experiences that differ in individuals. Psilocybin is a psychedelic component found in the mushroom species Psilocybe cubensis. On the other hand, LSD’s origin was…

ThursdayDec 31, 2020 12:08 pm

Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy

Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs Cybin (NEO: CYBN), a mushroom life sciences company, is working to become the first to bring a psilocybin drug to market targeting major depressive disorder (“MDD”). According to the National Institute of Mental Health, more than 18 million people in the United States — and 300 million people worldwide — experience major depression.…

WednesdayDec 30, 2020 9:45 am

New Hampshire Supreme Court Supports Freedom for Psychedelic Use in Religious Ceremonies

Last week, the Supreme Court of New Hampshire overturned an earlier conviction of a resident from the North Country, whose charges of psilocybin mushroom possession were filed in 2018. The court ruled that the earlier conviction conflicted with the religion the defendant practices, which is Native American based. The sitting justices stated in a unanimous ruling that as compared to protections in the U.S. constitution, the right of religion in the New Hampshire constitution was stronger. Under the U.S. constitution, sterner balancing tests are required in the event that the illegal drugs in question are used for religious practices. The…

TuesdayDec 29, 2020 10:45 am

Psychedelic Medicines May Develop into $100 Billion Business Opportunity

Psychedelic drugs have shown a lot of potential with regard to managing various mental health conditions. Canaccord Genuity Capital Markets analyst Tania Gonsalves states that more investors are getting into the psychedelic space, which may be worth nearly $100 billion. The psychedelic space is also becoming more mainstream as more and more cities decriminalize psychedelics such as psilocybin. Santa Cruz, Denver and Oakland legalized psilocybin use with the state of Oregon becoming the first state in the United States to legalize the use of psilocybin in a therapeutic setting. Top psychedelic firms to watch include New Wave Holdings Corp. (CSE:…

MondayDec 28, 2020 3:30 pm

New Research Discovers Connection Between Psychedelic Experiences, Personality Traits

Psychedelic drugs such as LSD and psilocybin mushrooms are known to cause various effects on different people; those effects range from encounters with entities from out of this world to complete dissolution from the ego. The unique nature of these experiences makes it rather hard for researchers to make definite conclusions concerning the end results of indulging in these psychedelic substances. However, new research shows that there may be a way to forecast how an individual will respond to psychedelics based on a person’s personality. Psychiatrists originally discovered a link between psychedelic drug-related experiences and an individual’s personality structure in…

WednesdayDec 23, 2020 3:00 pm

Researchers Develop Synthetic Ibogaine to Treat Depression, Addiction

Ibogaine is a psychoactive substance that triggers hallucinations; the substance is found in the Apocynaceae family of plants. Ibogaine has been used in spiritual ceremonies by the Bwiti tribe of Gabon for centuries. However, it wasn’t until the ’50s that ibogaine became popular in the West as a treatment for depression and addiction. Despite this rising popularity, however, ibogaine isn’t a medicine per se as it may lead to heart attacks and it’s illegal in most countries. Still, it was used by researchers recently to develop a non-hallucinogenic, non-toxic chemical cousin that helps tackle addictive and depressive behaviors in rodents.…

WednesdayDec 23, 2020 12:53 pm

Pure Extracts Technologies (CSE: PULL) Signs LOI with PURICA(TM) to Further Research into Mushrooms Wellness Products

Pure Extracts Technologies revealed it had recently retained global consultancy to advise on application for Dealer’s License under Health Canada If granted, license would allow Company to cultivate, conduct research into, commercialize controlled substances Pure Extracts also announced it recently signed LOI to further cooperation with PURICA(TM)( in field of full-spectrum mushroom-derived wellness products and co-develop CBD, mushroom product combinations Partnership would ideally situate Company to benefit from growing consumer interest within functional mushroom - CBD oil wellness product segments Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company, recently revealed that it had begun the process towards…

TuesdayDec 22, 2020 3:15 pm

Psychedelic Company Carrying Out Trials for Coronavirus Treatment

The announcement of the coronavirus vaccines from Pfizer, Moderna and Oxford is a hopeful sign for many. Nonetheless, there’s still a lot that we do not know about the coronavirus infection. However, researchers continue to work diligently to learn more about the SARS-CoV-2 virus, which causes the infection. While the vaccines that have been made are not 100% effective, they are effective enough to help achieve herd immunity, which will assist in efforts to contain the virus that is spreading rapidly, overwhelming health-care facilities and killing without mercy. Many private firms are looking into coronavirus treatments, including Revive Therapeutics (CSE:…

MondayDec 21, 2020 11:00 am

Pure Extracts Technologies Corp. (CSE: PULL) Names Key Advisor; Targets Development of Mushroom Formulations

Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD. MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems. Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations. Pure Extracts Technologies (CSE: PULL) has established a key collaborative relationship with an expert in translating pharmaceutical knowledge into a sustainable business. The plant-based extraction company, which is focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is working closely with Dr. Alexander MacGregor on developing quality cannabis…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000